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INTRODUCTION
In the US about 200,000 new breast cancer cases are diagnosed annually, and thousands die of the disease, often because the malignancy has become refractory to the treatment modalities that are now available. It is very important that we develop new therapeutic agents that are antioncotic by a mechanism different from those of current drugs. Our purpose is to develop such an agent that could be used as a first line treatment, solo or in combination with another agent, and that would have potential for use after other methods were no longer effective. Its use as a cancer preventive is possible. We have found that analogs of alphafetoprotein could be such an agent. They have anticancer activity utilizing a mechanism different from that of other drugs currently in use. Seeking new methods, several investigators have administered different pregnancy-associated hormones to carcinogen-treated rats and have observed significant reduction in breast cancer appearance. We think it is highly likely that such treatments elicit secretions of AFP, which in turn is the agent that inhibits cancer. Our experiments will determine whether the cancer inhibiting hormone treatments do in fact elicit the AFP which appears in the serum.
BODY Materials and Methods

Animals
Female Sprague Dawley rats were obtained from Taconic Farms at age 34 days and were placed immediately on a controlled diet (Agway Pro-Lab 2000; Agway Corporation, Syracuse, NY). They were allowed free access to food and water, and maintained on a 12-hour light-dark cycle at a constant temperature (22°C) for the duration of the study.
Carcinogen Treatment There were 30 rats in each experimental group (unless otherwise specified) to assure a 95% probability of detecting a difference between groups (ratios) of 40%, which was the difference seen for pregnancy . NMU was obtained from the National Cancer Institute carcinogen repository (MRI, Inc. Kansas City, MO) and was dissolved in sterile physiological saline, (1% w/v), buffered to pH 5.0 with 3% acetic acid. At 50 days of age, rats were randomized, and while under anesthesia were numbered using an ear punch, and a single intracarotid injection of NMU, 50mg/kg body weight was administered.
Hormone Treatments Each hormone treatment administered followed the doses and schedules specified in the publications being replicated.
Ten days following carcinogen administration, 30 female rats received 20ktg estradiol (E 2 , obtained from Sigma Aldrich, St. Louis, MO ) plus 4mg progesterone (P 4 ,obtained from Sigma Aldrich, St. Louis, MO) dissolved in sesame oil, daily, by 0.2ml subcutaneous injection, for 40 days.
E3 + P 4
Ten days following carcinogen administration, 30 female rats received two individual subcutaneous silastic capsules (0.078 inch IDx 0.125 inch OD, 2cm long; Dow Coming, Midland, MI, USA) packed with 30mg E 3 (Sigma Aldrich, St. Louis, MO) and 30mg P 4 (Sigma Aldrich, St. Louis, MO), respectively. Each silastic capsule was implanted subcutaneously dorsally, on either side of the upper spine, while animals were under isoflurane anesthesia. Implants were left in place for 21 days to mimic pregnancy, and then removed.
E3
Ten days following carcinogen administration, 30 female rats received a subcutaneous silastic capsule (0.078 inch IDx 0.125 inch OD, 2cm long; Dow Coming, Midland, MI, USA) packed with 30mg E 3 (Sigma Aldrich, St. Louis, MO). All silastic capsules were implanted subcutaneously dorsally, while animals were under isoflurane anesthesia. Implants were left in place for 21 days to mimic pregnancy, and then were removed.
HCG
Twenty-one days carcinogen administration, 30 female rats received an intraperitoneal injection of 100IU lyophilized Human chorionic gonadotropin, (Sigma Aldrich, St. Louis, MO) reconstituted with de-ionized water, pH 7.2 , daily, for 60 days.
Treatment with Pregnancy Ten days following carcinogen administration, 30 female rats were introduced to males (three females per male). Females stayed with males for 7 days, after which they were removed and separated. Twenty-one days later, 19 females bore litters, which were allowed to breast feed for 15 days. Females that did not become pregnant were excluded from the study.
Mammary Carcinogenesis
For tumor detection and monitoring of growth, animals were palpated twice weekly, starting at day 30 after NMU exposure for 123 days.
Statistics
The amount of inhibition provided by each hormone treatment was analyzed by comparing the percent incidence (number of rats bearing tumors) of the treatment with that of the NMU-only control (Fischer's Exact, P<0.05 was considered significant).
Blood Samples
Blood was drawn from each of the 6 groups of rats at 4 separate times; at the beginning, middle and end of the treatment, and once 14 days after the conclusion of the treatment.
Blood samples were collected from the tail vein. While rats were anesthetized under 3% isoflurane, I ml of blood was drawn with a 25G. Blood was transferred to glass centrifuge tubes and allowed to clot, uncovered, on the bench at room temperature for 4 hours. Serum was drawn off of each sample and spun 3 times (1500rpm, for 10 min) after which supernatant was collected. Samples were stored in at -80 C until used in AFP assay.
AFP Assays
Detection in sera is by Western Blot, and for estimation of concentration employed a standard curve. Gels (12% Tris-HC1, BioRad, Hercules, CA) were run containing different concentrations of amniotic fluid, maternal rat serum from the same animals, and serum from animals that received no hormone treatment.Gels were transferred onto blots and after blocking non-specific sites with 5% milk buffer in lx Tween Tris Buffered Saline (TTBS), blots were incubated overnight at 4°C with the primary antibody, goat anti rat AFP (Santa Cruz Biological, Santa Cruz, CA). Blots were rinsed with lx TTBS and incubated with the secondary antibody, rabbit anti goat IgG HRP (Santa Cruz Biological, Santa Cruz, CA). Blots were rinsed again and then developed using Western Lightning Western Blot Chemiluminescence Reagent (Perkin Elmer, Boston, MA).
Discussion
Five challenges of carcinogen-treated rats with different anticancer agents have been preformed during the year. The outcomes in terms of breast cancer appearance over time are shown in Figures 1-5 . Details of dosage amounts, routes and schedules appear in the legends to each figure. In each case the lower curve represents cancer appearance of animals in the tested group treated with an inhibitor, and the upper curve shows cancer appearance in a group of positive control rats (that received only carcinogen). Figure 2 . Breast Cancer Incidence in Estriol (E 3 ) + Progesterone (P 4 ) Treated Rats. Thirty Sprague-Dawley female virgin rats received NMU at the age of 50 days. Thirteen days after, rats received two subcutaneous silastic implants, containing 30mg estriol and 30mg progesterone respectively, which were left in place for 21 days, By Day 102, implants decreased tumor incidence by 33% p< 0.008. (Rajkumar et al, 2004 Figure 4 . Breast Cancer Incidence in Mated Female Rats. Thirty Sprague-Dawley female virgin rats received NMU at the age of 50 days. Ten days after, 30 female rats were introduced to males (three females per male). Females stayed with males for 7 days, after which they were removed and seperated. Twentyone days later, 19 females bore litters, which were allowed to breast feed for 15 days. Females that did not become pregnant were excluded from the study. By Day 123, pregnancy decreased tumor incidence by 28% p< 0.035. . Figure 5 . Breast Cancer Incidence in Human Chorionic Gonadotropin (hCG) Treated Rats. Twenty-one days after, rats were administered an i.p. injection of 100 IU hCG dissolved in de-ionized water daily, for a duration of 60 days. By Day 102, hCG treatment decreased tumor incidence by 30% p< 0.00 14. (Russo et al, 1990 ).
For each of the groups, twice weekly palpations were continued for as long as was economically prudent or for a shorter time when statistically significant inhibition had been produced. On the final day of palpation the portion of rats that had tumors (i.e. "incidence") was compared with the (higher) incidence in the NMU-only controls. The statistical significance of their differences were determined and is shown in Table 1 .
On day 102 the dimensions of each tumor were determined, and its volume estimated as an ellipsoid of revolution V= ir/6 d 2 D, where d and D are the respective short and long diameters. For each group mean volume per rat was calculated (Table 1 ). Our goal is to determine the rat AFP concentration in the 20 serum samples that have been collected from each of the six groups. To perform these assays by ELISA, three anti-rat AFP antibodies were obtained from Santa Cruz (Santa Cruz, CA). However, no pair of them could be successfully developed into an ELISA. One of the antibodies that reacted strongly with the rat AFP now has been developed into a Western Blot assay for the antigen. Using this method, we obtained a standard curve that provides a minimum detectable AFP concentration of Ing/ml, and this method is being employed for assay of rat sera.
